Novel humanized anti-ebola antibodies useful in preventing ebola infections
AssigneeThe Trustees of the University of Pennsylvania
InventorsMaria P. Limberis, Anna P. Tretiakova
Life of this patent
Estimating the term…
Abstract
A recombinant vector encoding a humanized 2G4 anti-ebola antibody (H2G4) is provided. Also provided is a recombinant vector encoding a humanized 4G7 anti-ebola antibody (H4G7). Compositions containing at least one of these humanized anti-ebola antibodies are provided. Also described are methods of improving survival against ebola infection in a human population which use these antibodies and compositions.
Claims23
A recombinant vector which comprises an expression cassette comprising the nucleic acid sequence encoding a humanized anti-ebola antibody under the control of regulatory sequences which direct expression of the antibody in target cells, wherein the anti-ebola antibody is selected from:
- (a) a humanized 2G4 anti-ebola antibody (H2G4) comprising:
- (i) a heavy chain comprising a variable region having the amino acid sequence of SEQ ID NO:
- 6 (H2G4VH);
- and
- (ii) a light chain comprising a variable region having the amino acid sequence of SEQ ID NO:
- 8 (H2G4VL);
- or
- (b) a humanized 4G7 anti-ebola antibody (H4G7) comprising:
- (i) a heavy chain comprising a variable region having the amino acid sequence of SEQ ID NO:
- 2 (H4G7VH);
- and
- (ii) a light chain comprising a variable region having the amino acid sequence of SEQ ID NO:
- 4 (H4G7VL).
A method for preventing ebola infection or improving survival rates against ebola in a human population comprising delivering an effective amount of a recombinant vector to a subject at risk of infection, wherein the recombinant vector which comprises an expression cassette comprising the nucleic acid sequence encoding a humanized anti-ebola antibody under the control of regulatory sequences which direct expression of the antibody in target cells, wherein the anti-ebola antibody is selected from:
- (a) a humanized 2G4 anti-ebola antibody (H2G4) comprising:
- (i) a heavy chain comprising a variable region having the amino acid sequence of SEQ ID NO:
- 6 (H2G4VH);
- and
- (ii) a light chain comprising a variable region having the amino acid sequence of SEQ ID NO:
- 8 (H2G4VL);
- or
- (b) a humanized 4G7 anti-ebola antibody (H4G7) comprising:
- (i) a heavy chain comprising a variable region having the amino acid sequence of SEQ ID NO:
- 2 (H4G7VH);
- and
- (ii) a light chain comprising a variable region having the amino acid sequence of SEQ ID NO:
- 4 (H4G7VL).
The method according to clam 16, wherein the second anti-ebola antibody is the same as that expressed from the recombinant vector, or wherein the second anti-ebola antibody is different from that expressed from the recombinant vector.
(canceled)
21-28. (canceled)
A recombinant humanized antibody which is useful in preventing infection with ebola virus, said antibody selected from:
- (a) a humanized 2G4 anti-ebola antibody (H2G4) comprising:
- (i) a heavy chain comprising a variable region having the amino acid sequence of SEQ ID NO:
- 6 (H2G4VH);
- and
- (ii) a light chain comprising a variable region having the amino acid sequence of SEQ ID NO:
- 8 (H2G4VL);
- or
- (b) a humanized 4G7 anti-ebola antibody (H4G7) comprising:
- (i) a heavy chain comprising a variable region having the amino acid sequence of SEQ ID NO:
- 2 (H4G7VH);
- and
- (ii) a light chain comprising a variable region having the amino acid sequence of SEQ ID NO:
- 4 (H4G7VL).
30-70. (canceled)
Dependencies are inferred from the claim text.